IL11 and pulmonary fibrosis: Hence, anti-IL11 therapeutics, which are advancing towards clinical trials in patients with PF, may promote alveolar regeneration and mitigate lung fibrosis that would differentiate anti-IL11 therapy from anti-fibrotics currently used in the clinic.